Charles T. Stier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles T. Stier has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Praveen N. Chander
New York Medical College
4 shared publicationsRicardo Rocha
Novartis Pharmaceuticals Corp
3 shared publicationsAndrea Zuckerman
2 shared publicationsLouis Rosenfeld
2 shared publicationsAliza Meissner
Department of Medicine, New York Medical College, Valhalla, NY, 10595, United States
1 shared publicationC. Andrew Powers
1 shared publication
Latest Publications
- 7 September 2021
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 34 (11) , 1143-1144
Commentary on Expression of Exogenous Epithelial Sodium Channel Beta Subunit in the Mouse Middle Cerebral Artery Increases Pressure-Induced Constriction
In this issue of the American Journal of Hypertension, Nemeth et al. report important new information regarding a potential role for the epithelial sodium channel (ENaC) in pressure-induced constriction/myogenic responses.1 Although ENaC is present in the late distal convoluted tubule, the connecting tubule, and the entire collecting duct of the kidney, it is now well known that it can be found elsewhere in the body including blood vessels.2 In the present study, the investigators took advantage of ex vivo transfection technology to overexpress ENaC in mouse middle cerebral arteries. Although previous studies have looked at the possible effects of inhibition of ENaC, the present studies provide new information in that...
- 7 September 2021
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 34 (11) , 1143-1144
Commentary on Expression of Exogenous Epithelial Sodium Channel Beta Subunit in the Mouse Middle Cerebral Artery Increases Pressure-Induced Constriction
In this issue of the American Journal of Hypertension, Nemeth et al. report important new information regarding a potential role for the epithelial sodium channel (ENaC) in pressure-induced constriction/myogenic responses.1 Although ENaC is present in the late distal convoluted tubule, the connecting tubule, and the entire collecting duct of the kidney, it is now well known that it can be found elsewhere in the body including blood vessels.2 In the present study, the investigators took advantage of ex vivo transfection technology to overexpress ENaC in mouse middle cerebral arteries. Although previous studies have looked at the possible effects of inhibition of ENaC, the present studies provide new information in that...
- Open Access
- 1 July 2018
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 137, 30-39
EET enhances renal function in obese mice resulting in restoration of HO-1-Mfn1/2 signaling, and decrease in hypertension through inhibition of sodium chloride co-transporter
- 1 July 2018
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 137, 30-39
Open AccessEET enhances renal function in obese mice resulting in restoration of HO-1-Mfn1/2 signaling, and decrease in hypertension through inhibition of sodium chloride co-transporter
- Open Access
- 28 December 2012
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 26 (2) , 151
Serotonin and Dopamine in Essential Hypertension
Serotonin is a biogenic amine that can be generated from its amino acid substrate, 5-hydroxytryptophan (5-HTP), by the enzyme L-aromatic amino acid decarboxylase (LAAD). L-aromatic amino acid decarboxylase has particularly high activity in the kidney, and is the same enzyme that converts L-3,4-dihydroxyphenylalanine (L-dopa) to dopamine. We have shown that infusion of 5-HTP directly into the isolated, non-blood-perfused rat kidney is associated with increases in perfusion pressure and serotonin formation, and have found that both of these effects were blocked by the inhibition of LAAD with carbidopa.1 However, carbidopa did not block the constrictor response to intrarenally injected serotonin. We also found that 5-HTP was readily converted to serotonin by rat kidneys in vivo, in that the intravenous infusion of 5-HTP markedly increased the urinary excretion of serotonin without any change in plasma levels of serotonin.2 Carbidopa markedly reduced the effect of 5-HTP on urinary serotonin excretion and reversed the attendant alterations in renal hemodynamics and salt and water excretion. These findings, together with our intrarenal infusion studies, are consistent with the intrarenal formation of serotonin by LAAD.
- 28 December 2012
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 26 (2) , 151
Open AccessSerotonin and Dopamine in Essential Hypertension
Serotonin is a biogenic amine that can be generated from its amino acid substrate, 5-hydroxytryptophan (5-HTP), by the enzyme L-aromatic amino acid decarboxylase (LAAD). L-aromatic amino acid decarboxylase has particularly high activity in the kidney, and is the same enzyme that converts L-3,4-dihydroxyphenylalanine (L-dopa) to dopamine. We have shown that infusion of 5-HTP directly into the isolated, non-blood-perfused rat kidney is associated with increases in perfusion pressure and serotonin formation, and have found that both of these effects were blocked by the inhibition of LAAD with carbidopa.1 However, carbidopa did not block the constrictor response to intrarenally injected serotonin. We also found that 5-HTP was readily converted to serotonin by rat kidneys in vivo, in that the intravenous infusion of 5-HTP markedly increased the urinary excretion of serotonin without any change in plasma levels of serotonin.2 Carbidopa markedly reduced the effect of 5-HTP on urinary serotonin excretion and reversed the attendant alterations in renal hemodynamics and salt and water excretion. These findings, together with our intrarenal infusion studies, are consistent with the intrarenal formation of serotonin by LAAD.
- Open Access
- 1 September 2010
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 23 (9) , 940
Aldosterone and Angiogenesis
Since its discovery in the early 1950s, aldosterone has been shown to have a major influence on renal electrolyte transport. However, it is now known that aldosterone also has important actions to promote fibrosis,1 thrombosis,2 and vascular inflammation.3 An action which has received much less consideration is the ability of aldosterone to influence angiogenesis. Angiogenesis is the formation of new blood vessels. The regulation of angiogenesis is through the release of stimulatory growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietins or inhibitory factors such as angiostatin and endostatin. Studies by Suzuki and coworkers showed that treatment with the selective mineralocorticoid receptor (MR) antagonist eplerenone (20 mg/kg/day) for 3 months in dogs subjected to progressive left ventricular dysfunction as a consequence of intracoronary microembolization substantially increased myocardial capillary density and basic FGF.4 These changes were accompanied by an improvement in cardiac ejection fraction and no change in arterial blood pressure. An increase in cardiac angiogenesis would be of particular benefit in patients postmyocardial infarction as it can provide blood flow and oxygen to support metabolism.
- 1 September 2010
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 23 (9) , 940
Open AccessAldosterone and Angiogenesis
Since its discovery in the early 1950s, aldosterone has been shown to have a major influence on renal electrolyte transport. However, it is now known that aldosterone also has important actions to promote fibrosis,1 thrombosis,2 and vascular inflammation.3 An action which has received much less consideration is the ability of aldosterone to influence angiogenesis. Angiogenesis is the formation of new blood vessels. The regulation of angiogenesis is through the release of stimulatory growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietins or inhibitory factors such as angiostatin and endostatin. Studies by Suzuki and coworkers showed that treatment with the selective mineralocorticoid receptor (MR) antagonist eplerenone (20 mg/kg/day) for 3 months in dogs subjected to progressive left ventricular dysfunction as a consequence of intracoronary microembolization substantially increased myocardial capillary density and basic FGF.4 These changes were accompanied by an improvement in cardiac ejection fraction and no change in arterial blood pressure. An increase in cardiac angiogenesis would be of particular benefit in patients postmyocardial infarction as it can provide blood flow and oxygen to support metabolism.
- 1 December 2009
- Published by Wolters Kluwer Health in Hypertension
- Vol. 54 (6) , 1211-1212
Mineralocorticoid Receptors in Myocardial Infarction
- 1 December 2009
- Published by Wolters Kluwer Health in Hypertension
- Vol. 54 (6) , 1211-1212
Mineralocorticoid Receptors in Myocardial Infarction
- 1 March 2006
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 19 (3) , 298-299
Osteopontin in Patients With Primary Aldosteronism
- 1 March 2006
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 19 (3) , 298-299
Osteopontin in Patients With Primary Aldosteronism
- 1 January 2005
- Published by Springer Nature in Heart Failure Reviews
- Vol. 10 (1) , 53-62
Effect of Aldosterone and MR Blockade on the Brain and the Kidney
The renin-angiotensin-aldosterone system (RAAS) plays a central role in the development of hypertension and the progression of end-organ damage. Although angiotensin-I converting enzyme (ACE) inhibitors and angiotensin II (Ang II) subtype-1 (AT1) receptor antagonists can initially suppress plasma aldosterone, it is now well established that aldosterone escape may occur whereby aldosterone levels return to, or exceed, baseline levels. The classical effects of aldosterone relate mainly to its action on epithelial cells to regulate water and electrolyte balance. However, the presence of mineralocorticoid receptors (MR) at nonepithelial sites in the brain, heart and vasculature, is consonant with the fact that aldosterone also has direct effects in these tissues. Substantial evidence now exists that supports the action of aldosterone at non-epithelial sites which in turn provokes a number of deleterious effects on the cardiovascular system including necrosis and fibrosis of the vasculature and the heart, vascular stiffening and injury, reduced fibrinolysis, endothelial dysfunction, catecholamine release and production of cardiac arrhythmias. Several studies have now shown that vascular and target-organ protective effects of MR antagonism occurs in the absence of significant blood pressure lowering or fluid loss, which is consistent with a major role for endogenous mineralocorticoids as direct mediators of cardiovascular injury. Adverse cardiovascular effects may occur in response to aldosterone alone, activation of the RAAS or aldosterone escape during chronic ACE inhibition or AT1 receptor antagonism. The specific blockade of aldosterone action should prove to be of great therapeutic value in the prevention of cerebral and renal vascular disease and associated end-organ damage.
- 1 January 2005
- Published by Springer Nature in Heart Failure Reviews
- Vol. 10 (1) , 53-62
Effect of Aldosterone and MR Blockade on the Brain and the Kidney
The renin-angiotensin-aldosterone system (RAAS) plays a central role in the development of hypertension and the progression of end-organ damage. Although angiotensin-I converting enzyme (ACE) inhibitors and angiotensin II (Ang II) subtype-1 (AT1) receptor antagonists can initially suppress plasma aldosterone, it is now well established that aldosterone escape may occur whereby aldosterone levels return to, or exceed, baseline levels. The classical effects of aldosterone relate mainly to its action on epithelial cells to regulate water and electrolyte balance. However, the presence of mineralocorticoid receptors (MR) at nonepithelial sites in the brain, heart and vasculature, is consonant with the fact that aldosterone also has direct effects in these tissues. Substantial evidence now exists that supports the action of aldosterone at non-epithelial sites which in turn provokes a number of deleterious effects on the cardiovascular system including necrosis and fibrosis of the vasculature and the heart, vascular stiffening and injury, reduced fibrinolysis, endothelial dysfunction, catecholamine release and production of cardiac arrhythmias. Several studies have now shown that vascular and target-organ protective effects of MR antagonism occurs in the absence of significant blood pressure lowering or fluid loss, which is consistent with a major role for endogenous mineralocorticoids as direct mediators of cardiovascular injury. Adverse cardiovascular effects may occur in response to aldosterone alone, activation of the RAAS or aldosterone escape during chronic ACE inhibition or AT1 receptor antagonism. The specific blockade of aldosterone action should prove to be of great therapeutic value in the prevention of cerebral and renal vascular disease and associated end-organ damage.
- 1 July 2004
- Published by Elsevier in European Journal of Pharmacology
- Vol. 495 (2-3) , 167-170
Stress triggered rise in plasma aldosterone is lessened by chronic nicotine infusion
- 1 July 2004
- Published by Elsevier in European Journal of Pharmacology
- Vol. 495 (2-3) , 167-170
Stress triggered rise in plasma aldosterone is lessened by chronic nicotine infusion
- Open Access
- 1 September 2003
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 21 (3) , 169-184
Eplerenone: A Selective Aldosterone Blocker
Recent studies suggest that aldosterone may play a larger role than once appreciated in normal physiologic function and cardiovascular disease. Some of the adverse cardiovascular effects that have been described include cardiac and vascular fibrosis, vascular necrosis and inflammation, impaired endothelial function, reduced fibrinolysis, hypertension, left ventricular hypertrophy (LVH), congestive heart failure, and cardiac arrhythmias. In light of these findings, the ability to block the actions of aldosterone has gained increased therapeutic importance. Eplerenone is a selective aldosterone receptor blocker that displays little interaction with androgen and progesterone receptors. Eplerenone has already been approved for the treatment of systemic hypertension and has been evaluated in numerous hypertension subgroups, including patients with low plasma renin activity; diabetes; LVH; uncontrolled blood pressure while receiving monotherapy with angiotensin‐converting enzyme inhibitors, angiotensin‐receptor blockers, calcium channel blockers, or beta‐blockers; and in black patients. Results of these trials indicate that eplerenone lowers blood pressure and reduces end‐organ damage. Further proof of the therapeutic importance of mineralocorticoid receptor blockade comes from the eplerenone post acute myocardial infarction survival and efficacy study (EPHESUS). In this large‐scale clinical outcome trial, eplerenone was shown to reduce total mortality by 15% as well as the combined endpoint of cardiovascular mortality/cardiovascular hospitalization by 13% when administered at a mean of 7.3 days post myocardial infarction to patients with evidence of systolic left ventricular dysfunction and symptoms of heart failure. Eplerenone is well tolerated, with an adverse effect profile comparable to placebo. The advent of selective aldosterone blockers, such as eplerenone, should prove to be of great therapeutic value in hypertension control and prevention of cardiovascular disease and associated end‐organ damage.
- 1 September 2003
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 21 (3) , 169-184
Open AccessEplerenone: A Selective Aldosterone Blocker
Recent studies suggest that aldosterone may play a larger role than once appreciated in normal physiologic function and cardiovascular disease. Some of the adverse cardiovascular effects that have been described include cardiac and vascular fibrosis, vascular necrosis and inflammation, impaired endothelial function, reduced fibrinolysis, hypertension, left ventricular hypertrophy (LVH), congestive heart failure, and cardiac arrhythmias. In light of these findings, the ability to block the actions of aldosterone has gained increased therapeutic importance. Eplerenone is a selective aldosterone receptor blocker that displays little interaction with androgen and progesterone receptors. Eplerenone has already been approved for the treatment of systemic hypertension and has been evaluated in numerous hypertension subgroups, including patients with low plasma renin activity; diabetes; LVH; uncontrolled blood pressure while receiving monotherapy with angiotensin‐converting enzyme inhibitors, angiotensin‐receptor blockers, calcium channel blockers, or beta‐blockers; and in black patients. Results of these trials indicate that eplerenone lowers blood pressure and reduces end‐organ damage. Further proof of the therapeutic importance of mineralocorticoid receptor blockade comes from the eplerenone post acute myocardial infarction survival and efficacy study (EPHESUS). In this large‐scale clinical outcome trial, eplerenone was shown to reduce total mortality by 15% as well as the combined endpoint of cardiovascular mortality/cardiovascular hospitalization by 13% when administered at a mean of 7.3 days post myocardial infarction to patients with evidence of systolic left ventricular dysfunction and symptoms of heart failure. Eplerenone is well tolerated, with an adverse effect profile comparable to placebo. The advent of selective aldosterone blockers, such as eplerenone, should prove to be of great therapeutic value in hypertension control and prevention of cardiovascular disease and associated end‐organ damage.
- 1 July 2003
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 285 (1) , E232-E239
Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats
Estrogen produces both beneficial and adverse effects on cardiovascular health via mechanisms that remain unclear. Stroke-prone spontaneously hypertensive rats (SHRSP) maintained on Stroke-Prone Rodent Diet and 1% NaCl drinking water (starting at 8 wk of age) rapidly develop stroke and malignant nephrosclerosis that can be prevented, despite continued hypertension, by drugs targeting angiotensin II and aldosterone actions. This study evaluated estrogen's effects in the SHRSP model. Female SHRSP that were sham operated (SHAM), ovariectomized (OVX) at 4 wk of age, or OVX and treated with estradiol benzoate (E2,30 μg·kg-1·wk-1) were studied. In a survival protocol, OVX rats lived significantly longer (15.1 ± 0.3 wk) compared with SHAM (13.6 ± 0.2 wk) or OVX+E2rats (12.4 ± 0.2 wk). In a protocol in which animals were matched for age, at 11.5 wk, terminal systolic blood pressure and urine protein excretion were elevated in SHAM and OVX+E2rats compared with OVX rats; blood urea nitrogen, renal microvascular and glomerular lesions, and plasma renin concentration were elevated in OVX+E2relative to SHAM or OVX rats. In a survival protocol using intact female SHRSP, treatment with an antiestrogen (tamoxifen, 7 mg·kg-1·wk-1) prolonged survival by >2 wk compared with controls ( P < 0.01). The data indicate that estrogen promotes microangiopathy in the kidney and stroke in saline-drinking SHRSP.
- 1 July 2003
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 285 (1) , E232-E239
Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats
Estrogen produces both beneficial and adverse effects on cardiovascular health via mechanisms that remain unclear. Stroke-prone spontaneously hypertensive rats (SHRSP) maintained on Stroke-Prone Rodent Diet and 1% NaCl drinking water (starting at 8 wk of age) rapidly develop stroke and malignant nephrosclerosis that can be prevented, despite continued hypertension, by drugs targeting angiotensin II and aldosterone actions. This study evaluated estrogen's effects in the SHRSP model. Female SHRSP that were sham operated (SHAM), ovariectomized (OVX) at 4 wk of age, or OVX and treated with estradiol benzoate (E2,30 μg·kg-1·wk-1) were studied. In a survival protocol, OVX rats lived significantly longer (15.1 ± 0.3 wk) compared with SHAM (13.6 ± 0.2 wk) or OVX+E2rats (12.4 ± 0.2 wk). In a protocol in which animals were matched for age, at 11.5 wk, terminal systolic blood pressure and urine protein excretion were elevated in SHAM and OVX+E2rats compared with OVX rats; blood urea nitrogen, renal microvascular and glomerular lesions, and plasma renin concentration were elevated in OVX+E2relative to SHAM or OVX rats. In a survival protocol using intact female SHRSP, treatment with an antiestrogen (tamoxifen, 7 mg·kg-1·wk-1) prolonged survival by >2 wk compared with controls ( P < 0.01). The data indicate that estrogen promotes microangiopathy in the kidney and stroke in saline-drinking SHRSP.